First Majestic Silver (AG) Q3 2026 Earnings Call Transcript
Source: The Motley Fool
First Majestic reported Q3 revenue of $394.1 million, up 38% year over year, and EBITDA of $228.8 million, up 78%, as higher realized metal prices offset lower production; net earnings attributable to owners were $74.5 million, including a $30.7 million one-time tax settlement expense. Silver production fell 11% to 3.4 million ounces, while AISC rose 46% to $30.45 per silver-equivalent ounce; San Dimas operations remain suspended amid a labor dispute after 12 days of lost production in Q3. The company reported $1.23 billion in total treasury, is investing in the Jerritt Canyon restart, and declared a $0.0142-per-share Q3 dividend.
Analysis
The key issue is whether unusually strong metal prices can keep masking weaker operating delivery. The San Dimas shutdown makes AG’s near-term production and cash generation less dependable precisely when price-driven margins are strongest; a prolonged dispute would turn an earnings beat into a guidance-credibility problem. Mexico labor costs also have convexity: profit-linked bonuses rise with metals prices, while management’s decision not to cover employees’ tax liabilities risks extending the outage. That is a company-specific risk premium, not a thesis on silver.
Reported AISC is a poor standalone signal here: management attributes much of the increase to a less favorable silver-equivalent conversion ratio, alongside lower grades and sustaining development. The more consequential test is realized cash margin after the strike and elevated investment, not the headline unit cost. Treasury provides a buffer, but Jerritt Canyon and mine development convert liquidity into execution risk before they deliver durable output. Verify the restart schedule and 2027 capital needs: the call’s stated Q4 2026 first-pour objective sits uneasily beside equipment deliveries extending into 2027.
Near term, the court process and San Dimas restart are the dominant catalysts; over 1–3 months, tax-framework implementation and updated Jerritt guidance matter. Over 6–18 months, successful development could improve production breadth, but delays or lower grades would expose AG to both operating leverage and capital-spend slippage. The contrarian point: price-driven EBITDA growth may be mistaken for operational improvement. Conversely, treating the AISC increase as pure cost inflation overstates deterioration.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
Key Decisions for Investors
- Avoid chasing the earnings reaction; keep AG underweight versus unhedged silver exposure until San Dimas resumes and management quantifies lost output. This limits strike-specific downside while retaining metal-price exposure elsewhere.
- For existing AG exposure, consider a relative-value hedge: short AG against a long silver instrument, sized to reduce company-specific risk rather than make a directional silver call. Reassess promptly on a court ruling or confirmed restart; the hedge can lose if the strike resolves quickly and AG rebounds.
- Treat a sustained San Dimas shutdown, weaker quarterly production guidance, or Jerritt Canyon schedule/capex slippage as thesis falsifiers for the recovery case. Monitor realized cash flow and mine output alongside AISC.
- Do not assign value to the remaining Mexican tax resolution yet. Request the payment schedule, total liability and release conditions; the announced framework remains incomplete, and the restricted-cash treatment cannot be inferred from the call.
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- AI stocks plunge after election, driving down US markets
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Iran says tankers struck in Hormuz amid fears of new US attack
- The Iran war has cost U.S. households nearly $2,000 each. New strikes could keep the bill climbing
- We're raising our price target on Cardinal Health after another stellar quarter of profits